Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Sildenafil for erectile dysfunction in the middle east: Observational analysis of patients with diabetes and/or hypertension treated in the clinical practice setting
Journal of International Medical Research, Volume 39, No. 2, Year 2011
Notification
URL copied to clipboard!
Description
The effectiveness and tolerability of 12 weeks of open-label treatment with sildenafil citrate for erectile dysfunction (ED) associated with a diagnosis of diabetes mellitus and/or hypertension were assessed in clinical practice in three Middle Eastern countries. The dose was initially 50 mg and was adjusted by the physician as needed (permissible dose range 25 - 100 mg). Total mean ± SD score on the five-item version of the International Index of Erectile Function (severe ED, score 0 - 7; no ED, score 22 - 25) was 13.6 ± 5.7 at baseline (4556 patients) and increased significantly to 21.7 ± 4.1 at week 12. Global effectiveness was rated as good or very good by 91.4% of patients, 93.9% rating their sexual activity as spontaneous and 91.4% as natural. Discontinuation of sildenafil due to adverse events was infrequent (0.5%). Tolerability was rated as good or very good by 95.7% of patients. It is concluded that sildenafil was a well-tolerated and highly effective treatment of ED in outpatients with diabetes and/or hypertension from the three Middle Eastern countries studied. © 2011 Field House Publishing LLP.
Authors & Co-Authors
El-Sakka, Ahmed I.
Egypt, Ismailia
Faculty of Medicine
Saudi Arabia, Makkah
Al Noor Specialist Hospital
Anis, Tarek H.
Egypt, Giza
Cairo University
Khadr, N.
United Arab Emirates, Dubai
Khadr Cardiology Clinic
Ismail, T. A.
United States, New York
Pfizer Inc.
Hegazy, Ahmed
United States, New York
Pfizer Inc.
Fekry, Osama
United States, New York
Pfizer Inc.
Youseif, E.
United States, New York
Pfizer Inc.
Statistics
Citations: 7
Authors: 7
Affiliations: 5
Identifiers
Doi:
10.1177/147323001103900225
ISSN:
03000605
Research Areas
Noncommunicable Diseases
Sexual And Reproductive Health